Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 189 followers
Latest posts
Last updated 7 days ago
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
7 days ago
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is...
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
11 days ago
THOUSAND OAKS, Calif. , Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
15 days ago
THOUSAND OAKS, Calif. , Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
15 days ago
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events...
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
17 days ago
THOUSAND OAKS, Calif. , Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
29 days ago
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
about 1 month ago
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List...
/C O R R E C T I O N -- Amgen/
about 1 month ago
In the news release, AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT...
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
about 1 month ago
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments...
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
about 2 months ago
THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2 months ago
THOUSAND OAKS, Calif. and TOKYO , Sept. 8, 2025 /PRNewswire/ -- Amgen...
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
2 months ago
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...